Earlier initiation of diabetes medications can lead to reduced heart disease risk in type 2 patients.

Management of non-glycemic cardiovascular disease risk factors may have increasing benefits in an aging type 1 diabetes patient population with long-term hyperglycemia.

Guest Post by David Kliff, Diabetic Investor. New diabetes technology sounds promising, but will products like One Drop really change patients' -- or payers' -- behavior?

Which of the following are strict or relative contraindications to the use of some of the GLP-1 agonists? A. Multiple endocrine neoplasia (MEN) syndrome type 2 B. Personal or family history of medullar thyroid cancer C. Pancreatitis D. All of the above Follow the link to see the right answer.

Do you think that a single-payer heathcare system would help to provide better care at less cost? Follow the link to share your opinion.

In this week's Homerun Slides, the implications of new guidelines for the preservation of beta cells.

Insulin action dynamics: Insulin sensitivity from the clamp is expressed in terms of the steady-state value reached after a period of hyperinsulinemia. A dose–response can be constructed and sensitivity can be expressed as the ED50, that is, the concentration for half-maximal stimulation of Rd as a function of dose. Alternatively, sensitivity can be expressed (as it usually is) as the Rd at a specific dose of insulin, which may be low, intermediate, or a maximum dose. It is often assumed that steady-state rate of glucose uptake is reached by 180 min after onset of the insulin infusion. In fact, steady-state glucose uptake is not reached at 3h. Glucose uptake rate at 3h is only 2/3 the “true” steady-state, which is not achieved until 6h. Certainly, shorter periods (e.g. 120 min) are inadequate to reflect steady-state rates of uptake.

Increase in BMI and A1c leads to coronary issues.

Long-term uncontrolled glycemic levels primary cause of complication.

This is an easy-to-use app that auto-logs daily blood sugars, insulin use, diet and activity data via connected devices. This app version allows patients to share Excel docs and PDFs of glucose history and other data to help providers make decisions about titrating insulin and advising on dietary modifications to tighten glycemic control.